What's New in Atopic Dermatitis

Yael Renert-Yuval; Emma Guttman-Yassky

doi:10.1016/j.det.2018.12.007

What's New in Atopic Dermatitis

Yael Renert-Yuval
, Emma Guttman-Yassky

Research output: Contribution to journal › Review article › peer-review

57 Scopus citations

Abstract

The evolving discoveries in atopic dermatitis (AD) shed light on disease pathogenesis and allow better management of patients. Dupiluamab was the first targeted agent approved for AD, proving for the first time AD can be treated with a single cytokine antagonism. Nevertheless, because not all patients respond to dupilumab and AD has a heterogeneous phenotype, more treatment options are much needed. This article reviews recent and exciting developments in AD, because ongoing or pipeline clinical trials for AD will ultimately expand and redefine a novel treatment paradigm for this common disease.

Original language	English
Pages (from-to)	205-213
Number of pages	9
Journal	Dermatologic Clinics
Volume	37
Issue number	2
DOIs	https://doi.org/10.1016/j.det.2018.12.007
State	Published - Apr 2019

Keywords

Atopic dermatitis
Crisaborole
Dupiluamb
Fezakinumab
GBR 830
JAK inhibitors
Lebrikizumab
Tralokinumab

Access to Document

10.1016/j.det.2018.12.007

Cite this

@article{43ae6a0a9499469db20fa4fbffa40258,

title = "What's New in Atopic Dermatitis",

abstract = "The evolving discoveries in atopic dermatitis (AD) shed light on disease pathogenesis and allow better management of patients. Dupiluamab was the first targeted agent approved for AD, proving for the first time AD can be treated with a single cytokine antagonism. Nevertheless, because not all patients respond to dupilumab and AD has a heterogeneous phenotype, more treatment options are much needed. This article reviews recent and exciting developments in AD, because ongoing or pipeline clinical trials for AD will ultimately expand and redefine a novel treatment paradigm for this common disease.",

keywords = "Atopic dermatitis, Crisaborole, Dupiluamb, Fezakinumab, GBR 830, JAK inhibitors, Lebrikizumab, Tralokinumab",

author = "Yael Renert-Yuval and Emma Guttman-Yassky",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2019",

month = apr,

doi = "10.1016/j.det.2018.12.007",

language = "English",

volume = "37",

pages = "205--213",

journal = "Dermatologic Clinics",

issn = "0733-8635",

publisher = "W.B. Saunders",

number = "2",

}

TY - JOUR

T1 - What's New in Atopic Dermatitis

AU - Renert-Yuval, Yael

AU - Guttman-Yassky, Emma

PY - 2019/4

Y1 - 2019/4

N2 - The evolving discoveries in atopic dermatitis (AD) shed light on disease pathogenesis and allow better management of patients. Dupiluamab was the first targeted agent approved for AD, proving for the first time AD can be treated with a single cytokine antagonism. Nevertheless, because not all patients respond to dupilumab and AD has a heterogeneous phenotype, more treatment options are much needed. This article reviews recent and exciting developments in AD, because ongoing or pipeline clinical trials for AD will ultimately expand and redefine a novel treatment paradigm for this common disease.

AB - The evolving discoveries in atopic dermatitis (AD) shed light on disease pathogenesis and allow better management of patients. Dupiluamab was the first targeted agent approved for AD, proving for the first time AD can be treated with a single cytokine antagonism. Nevertheless, because not all patients respond to dupilumab and AD has a heterogeneous phenotype, more treatment options are much needed. This article reviews recent and exciting developments in AD, because ongoing or pipeline clinical trials for AD will ultimately expand and redefine a novel treatment paradigm for this common disease.

KW - Atopic dermatitis

KW - Crisaborole

KW - Dupiluamb

KW - Fezakinumab

KW - GBR 830

KW - JAK inhibitors

KW - Lebrikizumab

KW - Tralokinumab

UR - https://www.scopus.com/pages/publications/85061591061

U2 - 10.1016/j.det.2018.12.007

DO - 10.1016/j.det.2018.12.007

M3 - Review article

C2 - 30850043

AN - SCOPUS:85061591061

SN - 0733-8635

VL - 37

SP - 205

EP - 213

JO - Dermatologic Clinics

JF - Dermatologic Clinics

IS - 2

ER -

What's New in Atopic Dermatitis

Abstract

Keywords

Access to Document

Fingerprint

Cite this